MEDICINE FOR PROTECTING THE LIVER, REMOVING TOXINS, REDUCING BLOOD LIPIDS AND REDUCING BLOOD SUGAR AND USE THEREOF
    3.
    发明公开
    MEDICINE FOR PROTECTING THE LIVER, REMOVING TOXINS, REDUCING BLOOD LIPIDS AND REDUCING BLOOD SUGAR AND USE THEREOF 审中-公开
    药肝的对废水毒素,要降低血脂,血糖和使用还原其保护

    公开(公告)号:EP3078382A1

    公开(公告)日:2016-10-12

    申请号:EP15722345.4

    申请日:2015-03-10

    申请人: Zhao, Junhong

    发明人: Zhao, Junhong

    摘要: The present invention provides a drug showing liver protection, detoxification, lipid-lowering and hypoglycemic properties and use thereof, which is a formulation prepared from a starting material comprising, in parts by weight, 10-35 parts of the root of Trichosanthes cucumeroides (Ser.) Maxim, 5-20 parts of the root of Radix Sophorae Flavescentis, 15-30 parts of Tartary Buckwheat, 15-25 parts of the root of Rhizoma Dioscorea, 10-35 parts of the root of Kudzu Vine and 10-25 parts of pollen. It is useful in the manufacturing of a medicament for treating liver diseases, in the manufacturing of a medicament for treating hyperlipidemia or in the manufacturing of a medicament for treating diabetes. The drug of the present invention takes advantages of the medicinal properties of the root of Trichosanthes cucumeroides (Ser.) Maxim and the root of Radix Sophorae Flavescentis, to achieve liver-clearing and cholagogue effects, and a therapeutical effect on jaundice and chronic hepatitis, in combination with the spleen-nourishing, Qi-regulating, pathogenic wind-dispelling and phlegm-eliminating properties of Tartary Buckwheat, the spleen-nourishing, appetizing, deficiency restoring properties of the root of Rhizoma Dioscorea, the deficient heat clearing and alcoholism relieving properties of the root of Kudzu Vine, and the thirst relieving and jaundice clearing properties of pollen. Thus, liver protection, detoxification, lipid-lowering and hypoglycemic effects can be achieved by the drug of the present invention. The drug of the present invention further provides the following advantages: its raw materials can be obtained from abundant sources; its formulation can be prepared using conventional processes, through simple procedures, and at a low cost; it is much worthy of promotion and application, and has a promising market prospect and a vast space for development.

    摘要翻译: 本发明提供了一种药物显示保肝,解毒,降脂和降血糖特性,并使用它们,所有这些是从起始材料制备的制剂,其包含,(按重量份计,10-35份的栝楼根cucumeroides丝氨酸 。)马克西姆,5-20份苦参的根部,15-30份苦荞麦的,15-25份羌活薯蓣的根部,10-35份葛根和10-25份的根部的 花粉。 它是用于治疗肝脏疾病,在制造用于治疗治疗高脂血症或在制备用于治疗糖尿病的药物中的制造的药物中是有用的。 本发明的药物为(序列)马克西姆和苦参的根部的栝cucumeroides根的药性的优势,实现肝清算和利胆影响,以及对黄疸和慢性肝炎治疗作用, 与脾滋养,齐调节的组合,风邪-消解和苦荞麦,脾-滋补,开胃,缺乏恢复羌活薯蓣,不足的热交换的根部的性质的化痰消除性能和酒精中毒缓解性质 葛根的根部,和口渴的减轻黄疸和清除花粉的性质。 因此,保护​​肝脏,解毒,降脂和降血糖作用,可以通过本发明的药物来实现的。 本发明的药物还提供了以下优点:其原料可以从丰富的来源中获得; 其制剂可以使用常规的方法来制备,通过简单的程序,并且以较低的成本; 这是很值得推广和应用,并具有广阔的市场前景和广阔的发展空间。

    VERFAHREN ZUR HERSTELLUNG VON TROCKENEXTRAKTEN

    公开(公告)号:EP2744504A1

    公开(公告)日:2014-06-25

    申请号:EP12762228.0

    申请日:2012-08-20

    申请人: Bionorica SE

    发明人: POPP, Michael

    摘要: The invention relates to a method for producing dry extracts of plants and to pharmaceutical preparations containing the same, more particularly phytopharmaceuticals, which contain at least one ethanolic/aqueous extract of a plant (drug), the plants being selected from the group consisting of:
    Rumicis herba ;
    Verbena officinalis ;
    Sambucus nigra ;
    Primula veris ; and
    Gentiana lutea and mixtures thereof. The invention further relates to a pharmaceutical for treating inflammatory and/or infectious diseases of the nose and throat area and/or the nasal sinuses, as well as the use thereof.

    摘要翻译: 本发明涉及一种用于生产植物的干燥提取物的方法和含有该植物的药物制剂的方法,更特别是含有至少一种植物(药物)的乙醇/水提取物的植物药物,所述植物选自: 罗米is 马鞭草 黑曲霉 樱草属 和龙胆草及其混合物。 本发明还涉及用于治疗鼻部和喉部区域和/或鼻窦炎症和/​​或感染性疾病的药物及其用途。

    WIRKSTOFFFRAKTIONEN FÜR FORMULIERUNGEN ZUR THERAPIE UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN
    6.
    发明公开
    WIRKSTOFFFRAKTIONEN FÜR FORMULIERUNGEN ZUR THERAPIE UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN 审中-公开
    活性基团,用于治疗和炎性疾病的预防制剂

    公开(公告)号:EP2004207A1

    公开(公告)日:2008-12-24

    申请号:EP07722137.2

    申请日:2007-03-30

    IPC分类号: A61K36/70

    CPC分类号: A61K36/70 A61K36/708

    摘要: The invention relates to antioxidant substance fractions produced from Rheum species for formulations for the therapy and prophylaxis of inflammatory or autoimmune diseases and/or diseases with disturbed keratinocyte proliferation. The active substance fractions are obtained by extraction of the dried and ground root samples with methanol, the aqueous phase so produced is liberated from lipophilic accompanying substances while completely removing the methanol, the purified aqueous phase is extracted by shaking with ethyl acetate, the resulting aqueous phase and the combined ethyl acetate phase are processed separately, separated by column chromatography to give a limited number of active substance fractions and the active substance fractions from the aqueous phase and from the ethyl acetate phase having the same spectrum of constituents are each combined.

    METHOD FOR PRODUCING NEPODIN-RICH EXTRACT OF RUMEX PLANT AND NEPODIN-RICH EXTRACT OF RUMEX PLANT

    公开(公告)号:EP3437648A1

    公开(公告)日:2019-02-06

    申请号:EP17773859.8

    申请日:2017-02-21

    IPC分类号: A61K36/70 A61K31/12

    摘要: An objective of the present invention is to provide a method for producing a nepodin-containing extract containing a high concentration of nepodin with less contaminants present therein thereby being able to be readily carried out on an industrial scale, when compared to the conventional techniques. The objective is solved by A method for producing a nepodin-containing Rumex plant extract, the method comprising the following steps (1) to (5):
    (1) a step of subjecting a Rumex plant to an extraction treatment using a nepodin-dissolving solvent to obtain a crude Rumex plant extract;
    (2) a step of subjecting the crude Rumex plant extract to a water-adding treatment and/or concentration treatment to obtain a solid crude Rumex plant extract;
    (3) a step of subjecting the solid crude Rumex plant extract to a weak alkali treatment to obtain a weak alkali insoluble product;
    (4) a step of subjecting the weak alkali insoluble product to a strong alkali treatment to obtain a strong alkali soluble product; and
    (5) a step of subjecting the strong alkali soluble product to a neutralization treatment to obtain the nepodin-containing Rumex plant extract.

    Pharmazeutische Zusammensetzung zur Behandlung von Borreliose

    公开(公告)号:EP2893935A1

    公开(公告)日:2015-07-15

    申请号:EP14197338.8

    申请日:2014-12-11

    摘要: Die vorliegende Erfindung stellt eine Zusammensetzung zur Verwendung in der Behandlung der Borreliose bereit, sowie ein Kit, das die Zusammensetzung umfasst. Die erfindungsgemäße Zusammensetzung umfasst vier Gruppen an Bestandteilen, wobei Gruppe A) 1000 - 5000 mg Katzenkralle, 1000 - 3000 mg Krillöl oder Kalamarinöl oder Kombinationen davon, 200 - 600 mg Magnesium Malat, 3000 - 5000 mg Ester C, 100 - 300 mg Alpha-Liponsäure, 25 - 75 mg Pyridoxal-5-phosphat (Vitamin B6), 6000 - 14000 IU Cholecalciferol (Vitamin D3), 2000 - 4000 mg He Shou Wu, 1200 - 2500 mg Rotklee Tee, 10 - 50 ml Petersiliensaft umfasst, Gruppe B) 2000 - 4000 mg Monolaurin, 400 - 800 mg N-Acetylcystein, 100 - 300 mg Hyaluronsäure mit BioCell Kollagen II und 1 - 7 Tropfen Karde Wurzel, Gruppe C) 10 - 70 Tropfen Spilanthes Acmella umfasst und Gruppe D) 500 - 1500 µg Cyanocobalamin (Vitamin B 12) umfasst. Die Zusammensetzung und das Kit eignen sich zur Verwendung in der Behandlung von Borreliose, wobei die Bestanteile der Gruppe A) einmal täglich verabreicht werden, die der Gruppe B) zweimal täglich, das der Gruppe C) dreimal täglich und das der Gruppe D) alle 14 Tage.

    摘要翻译: 本发明提供了用于治疗硼酸血症的组合物和试剂盒。 组合物包括四组组分,组A)组分1000-5000 mg Cat's Claw,1000-3000 mgs磷虾油或Kalamarine油或其组合,200-600 mgs苹果酸镁,3000-5000 mgs C,100 -300毫克α-硫辛酸,25-75毫克磷酸二肟基(维生素B6),6000-14000 IU胆钙化醇(维生素D3),2000-4000毫克何守武,1200-2500毫克紫色三叶草茶,10- 50毫升荷兰芹,B组)2000-4000毫克单硫酸,400-800毫克N-乙酰半胱氨酸,100-300毫克透明质酸与BioCell胶原II,1-5滴Teasel根,C组)10-70滴Spilanthes Acmella和D组)500-1500微克氰钴胺(维生素B12)。 该组合物和试剂盒适用于治疗硼复性,其中A组的成分每日一次,B组每日一次,C组每日两次,C组每日三次, D组)每14天。